» Articles » PMID: 34539883

Effect of EG00229 on Radiation Resistance of Lung Adenocarcinoma Cells

Overview
Journal J Cancer
Specialty Oncology
Date 2021 Sep 20
PMID 34539883
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Neuropilin 1 (NRP1) is a pleiotropic receptor that interacts with multiple ligands and their receptors and plays a critical role in the process of tumor metastasis and radiation resistance in endothelial cells and tumor cells. In this study, we sought to investigate the mechanistic role of NRP1 in the radiation resistance of non-small cell lung cancer (NSCLC) cells and the role of EG00229 (an inhibitor of NRP1) on reversing radiation resistance. A549 and H1299 NSCLC cells were used to construct radiation resistance models. Western blot, ELISA, and qRT-PCR were used to detect protein and mRNA levels of NRP1, epithelial-mesenchymal transition (EMT) markers, and molecules in signaling pathways. Immunofluorescence was used to measure changes in co-expression of NRP1 and VEGF-165 in radiation-resistant model cells. An immunoprecipitation assay was used to detect the binding capacity of NRP1 and VEGF-165. We successfully created two radiation resistant models (A549RR and H1299-RR). The expression levels of NRP1, EMT-related proteins, and proteins in metastasis-related pathways were increased in NSCLC cells with radiation resistance. After adding EG00229, the expression levels and binding capacity of NRP1 and VEGF-165 proteins were significantly reduced. The expression of EMT-related proteins and proteins in metastasis-related pathways were reduced in NSCLC cells with radiation resistance. Our data provide an insight into the molecular mechanisms of radiation resistance and suggest that EG00229 may contribute to reversing the radiation resistance of NSCLC cells by inhibiting the binding of NRP1 and VEGF-165. Our findings could provide a novel theoretical and experimental foundation for improving the efficacy of lung cancer radiotherapy.

Citing Articles

NRP1 overexpression potentially enhances osimertinib resistance in NSCLC via activation of the PI3K/AKT signaling pathway.

Wang Y, Wang B, Zhou L, Wan Y, Zheng Y, Zhou L Am J Cancer Res. 2025; 14(12):5680-5696.

PMID: 39803652 PMC: 11711526. DOI: 10.62347/RLVZ6860.


Radiation-induced YAP/TEAD4 binding confers non-small cell lung cancer radioresistance via promoting NRP1 transcription.

Wang M, Yi J, Gao H, Wei X, Xu W, Zhao M Cell Death Dis. 2024; 15(8):619.

PMID: 39187525 PMC: 11347582. DOI: 10.1038/s41419-024-07017-6.


The Nervous System Development Regulator Neuropilin-1 as a Potential Prognostic Marker and Therapeutic Target in Brain Cancer.

Rodrigues E, Giovanini A, Ribas C, Malafaia O, Roesler R, Isolan G Cancers (Basel). 2023; 15(20).

PMID: 37894289 PMC: 10605093. DOI: 10.3390/cancers15204922.


Hepatocellular carcinoma cells loss lenvatinib efficacy in vitro through autophagy and hypoxia response-derived neuropilin-1 degradation.

Fernandez-Palanca P, Payo-Serafin T, San-Miguel B, Mendez-Blanco C, Tunon M, Gonzalez-Gallego J Acta Pharmacol Sin. 2022; 44(5):1066-1082.

PMID: 36376373 PMC: 10104874. DOI: 10.1038/s41401-022-01021-2.


Current Landscape of Therapeutic Resistance in Lung Cancer and Promising Strategies to Overcome Resistance.

Ashrafi A, Akter Z, Modareszadeh P, Modareszadeh P, Berisha E, Alemi P Cancers (Basel). 2022; 14(19).

PMID: 36230484 PMC: 9558974. DOI: 10.3390/cancers14194562.


References
1.
Satelli A, Li S . Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci. 2011; 68(18):3033-46. PMC: 3162105. DOI: 10.1007/s00018-011-0735-1. View

2.
Kazemi M, Carrer A, Moimas S, Zandona L, Bussani R, Casagranda B . VEGF121 and VEGF165 differentially promote vessel maturation and tumor growth in mice and humans. Cancer Gene Ther. 2016; 23(5):125-32. DOI: 10.1038/cgt.2016.12. View

3.
Sasaki S, Baba T, Muranaka H, Tanabe Y, Takahashi C, Matsugo S . Involvement of Prokineticin 2-expressing Neutrophil Infiltration in 5-Fluorouracil-induced Aggravation of Breast Cancer Metastasis to Lung. Mol Cancer Ther. 2018; 17(7):1515-1525. DOI: 10.1158/1535-7163.MCT-17-0845. View

4.
Aiello N, Maddipati R, Norgard R, Balli D, Li J, Yuan S . EMT Subtype Influences Epithelial Plasticity and Mode of Cell Migration. Dev Cell. 2018; 45(6):681-695.e4. PMC: 6014628. DOI: 10.1016/j.devcel.2018.05.027. View

5.
Ko E, Raben D, Formenti S . The Integration of Radiotherapy with Immunotherapy for the Treatment of Non-Small Cell Lung Cancer. Clin Cancer Res. 2018; 24(23):5792-5806. DOI: 10.1158/1078-0432.CCR-17-3620. View